By BullScreen Editorial Team 
Dr. Lal PathLabs Limited reported its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, following approval by its Board of Directors.
The meeting marked a series of strategic and financial decisions, including dividend declaration, expansion initiatives, and leadership appointments.
The Board recommended a final dividend of ₹4 per equity share, taking the total FY26 dividend to ₹20.5 per share.
In a key strategic move, the company approved the acquisition of a 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL), a Mumbai-based diagnostics firm, for a consideration not exceeding ₹20 crore. The acquisition is expected to strengthen its footprint in Maharashtra and is likely to be completed by May 31, 2026.
Further expanding its global presence, the Board cleared the incorporation of a wholly owned subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE.
Additionally, the company allotted 82,750 equity shares under ESOP 2022, raising its paid-up capital to ₹1,676.38 crore.
| Metric | Value (₹ Million) | YoY Growth |
|---|---|---|
| Revenue from Operations | 27,629 | 12.25% |
| Total Income | 28,642 | 12.11% |
| Profit Before Tax (PBT) | 6,691 | 7.11% |
| Net Profit (PAT) | 5,098 | 3.58% |
| Earnings Per Share (EPS) | ₹30.24 | — |
For Q4 FY26, net profit came in at ₹1,322 million. The quarter’s PBT excluded an exceptional charge of ₹301 million related to the implementation of new labour codes.
| Category | Amount (₹ Million) | Notes |
|---|---|---|
| Total Expenses (FY26) | 21,650 | Up from ₹19,301 million in FY25 |
| Material Costs | 5,346 | Major cost component |
| Employee Benefits | 5,033 | Includes salaries & benefits |
| Collection Centre Fees | 4,024 | Distribution network costs |
| Exceptional Expense | 301 | One-time impact due to labour law changes |
As of March 31, 2026, Dr. Lal PathLabs Limited maintained a debt-free balance sheet with improved financial strength:
| Category | Metric | Value (₹ Million) | Notes |
|---|---|---|---|
| Balance Sheet | Total Assets | 31,460 | Up from ₹27,168 million |
| Cash & Investments | 10,800+ | Strong liquidity position | |
| Net Worth | 25,082 | Healthy equity base | |
| Cash Flow | Operating Cash Flow | 6,357 | Strong cash conversion |
| Investing Activities | (4,219) | Includes ₹1,670 million CAPEX | |
| Financing Activities | (2,536) | Mainly dividend payouts |
The company generated ₹6,357 million in operating cash flow, reflecting strong cash conversion. Investing outflows stood at ₹4,219 million, including ₹1,670 million in capital expenditure, while ₹2,536 million was used in financing activities, primarily dividend payouts.
With steady revenue growth, strong cash flows, and strategic expansion into Mumbai and international markets, Dr. Lal PathLabs Limited continues to strengthen its position as a leading diagnostics player in India while laying the groundwork for global expansion.
source:https://www.bseindia.com/xml-data/corpfiling/AttachLive/56e8b249-8360-4cc6-ba96-d99faf31bae0.pdf